title: 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced dual-specificity phosphatase expression and AML cell survival.
abstract: 12-O-Tetradecanoylphorbol-13-acetate (TPA) is being developed as a therapeutic agent by virtue of its being a potent modulator of signal transduction in pre-clinical models of AML [Strair RK, Schaar D, Goodell L, Aisner J, Chin KV, Eid J, et al. Administration of a phorbol ester to patients with hematological malignancies: preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate. Clin Cancer Res 2002;8:2512-8]. In this report, we identify a subset of primary AML samples that undergoes apoptosis after exposure to TPA and demonstrate that TPA-induced cytotoxicity is associated with modulation of the ERK signaling pathway. Analysis of mitogen-activated protein kinase (MAPK) dual-specificity phosphatases (DUSP), as potential regulators of AML cell signaling, indicates that these genes are coordinately regulated and rapidly induced by TPA in primary AML cells. Therefore, TPA-induced primary AML cytotoxicity is associated with modulation of ERK signaling which may be partially mediated by regulation of phosphatase expression.
authors.affiliation: The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey (UMDNJ), NJ, USA. schaardg@umdnj.edu
authors.forename: Dale G
authors.initials: DG
authors.lastname: Schaar
authors.forename: Hao
authors.initials: H
authors.lastname: Liu
authors.forename: Shashi
authors.initials: S
authors.lastname: Sharma
authors.forename: Yi
authors.initials: Y
authors.lastname: Ting
authors.forename: John
authors.initials: J
authors.lastname: Martin
authors.forename: Curtis
authors.initials: C
authors.lastname: Krier
authors.forename: Marie
authors.initials: M
authors.lastname: Ciardella
authors.forename: Mona
authors.initials: M
authors.lastname: Osman
authors.forename: Lauri
authors.initials: L
authors.lastname: Goodell
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Notterman
authors.forename: Roger K
authors.initials: RK
authors.lastname: Strair
mesh_terms: D000208:Acute Disease; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D002273:Carcinogens / Q000494:pharmacology*; D018797:Cell Cycle Proteins / Q000378:metabolism*; D002470:Cell Survival; D054638:Dual Specificity Phosphatase 1; D020869:Gene Expression Profiling; D006801:Humans; D017874:Immediate-Early Proteins / Q000378:metabolism*; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology; D019950:Mitogen-Activated Protein Kinase 1 / Q000235:genetics / Q000378:metabolism*; D048052:Mitogen-Activated Protein Kinase 3 / Q000235:genetics / Q000378:metabolism*; D020411:Oligonucleotide Array Sequence Analysis; D010749:Phosphoprotein Phosphatases / Q000378:metabolism*; D010766:Phosphorylation / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D054645:Protein Phosphatase 1; D017027:Protein Tyrosine Phosphatases / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction / Q000187:drug effects*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology*
chemical_list: D002273:Carcinogens; D018797:Cell Cycle Proteins; D017874:Immediate-Early Proteins; D047428:Protein Kinase Inhibitors; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D010749:Phosphoprotein Phosphatases; D054645:Protein Phosphatase 1; C517019:DUSP1 protein, human; D054638:Dual Specificity Phosphatase 1; D017027:Protein Tyrosine Phosphatases; D013755:Tetradecanoylphorbol Acetate